Allovectin-7 to Enlarge Gene Therapy Revenue Patterns

Allovectin-7 (velimogene aliplasmid) is anticipated to generate estimated revenue worth US$ 400 Million in the US after its projected launch in 2012-2013, says RNCOS.

Noida, India (prHWY.com) April 16, 2012 - According to a new research offering by RNCOS, "Global Gene Therapy Market Analysis", the global market for gene therapy has grown stupendously on the back of prominent factors, such as active private sector participation and impressive advancements in technologies. In fact, in less than a couple of decades, gene therapy has witnessed significant advancement as it progressed from the conceptual stage to the clinical trials stage in various indications. This, in turn, made the market attractive, thereby, boosting the sector to grow to the mark of US$ 485 Million by the end of 2011. In future, the market is likely to witness exceptional growth with the advent of new drugs in developed countries such as the US and Europe.

The report has found that Allovectin-7 (velimogene aliplasmid) is anticipated to generate estimated US$ 400 Million revenue in the US, after its projected launch in 2012-2013. AnGes MG has licensed rights to commercialize Allovectin-7 in several Asian countries, and is primarily interested in developing the same as a treatment for head and neck cancer. This indeed seems to meet a significant unmet medical need in Asia. Moreover, the Company expects to get the top line phase III results by the end of Q2 2012 for Allovectin-7 as first-line therapy in patients with Stage-III or -IV recurrent metastatic melanoma.

The report, spread over 115 pages, provides an extensive research and prudent analysis of the current status and expected position of the Global Gene Therapy Market. It provides comprehensive overview of the advanced gene therapy drugs along with recent industry developments to provide a balanced outlook on the market potential. Moreover, the report gives an effective insight into the gene therapy clinical trials that are being progressed in different phases of research and further analyzes the use of vectors in those studies.

The report is an outcome of an in-depth research of global gene therapy market that takes into accounts all the key industry developments and participants' activities. It also investigates the current market trends and elaborates their market impact. The report facilitates the future forecasts on overall Gene Therapy Market size by 2015. Moreover, it projects the potential market to be generated by key gene therapy products to be launched in future. It analyzes the opportunity assessment for companies in the global gene therapy market in terms of key vectors and leading technologies.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM282.htm

Some of our Related Reports are:

- Cancer Monoclonal Antibodies Market to 2015
(http://www.rncos.com/Report/IM375.htm)
- Global Biosimilars Market Forecast to 2015
(http://www.rncos.com/Report/IM379.htm)
- US Biotech Market Analysis (http://www.rncos.com/Report/IM0300.htm)
- Global miRNA Market Outlook (http://www.rncos.com/Report/IM286.htm)
- Global HIV Therapeutics Market Analysis (http://www.rncos.com/Report/IM361.htm)

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

About RNCOS

RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.

###

Tag Words: gene therapy pfizer

Categories: Biotech

Press Release Contact
B-129, Sector 6 Noida - 201301
91-120-4224-700
91-120-4224-707

Link To This Press Release:

URL HTML Code